Trial Profile
Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2019
Price :
$35
*
At a glance
- Drugs Cinaciguat (Primary)
- Indications Chronic heart failure; Decompensated heart failure; Heart failure
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 15 Jun 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 17 Jun 2009 Planned number of patients changed from 210 to 149 as reported by ClinicalTrials.gov.
- 17 Jun 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.